Clinical Trial Update: Perioperative TORIPALIMAB Plus LENVATINIB in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PLUTO) [Phase 2]

View source ↗

Summary

The Phase 2 PLUTO trial evaluating perioperative toripalimab plus lenvatinib in renal cell carcinoma patients undergoing nephrectomy has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• LENVIMA (lenvatinib)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Jinling Hospital, China | Conditions: Renal Cell Carcinoma (RCC) | Phase 2 | Status: TERMINATED